Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)

por Baron-Hay, Sally, Aapro, Matti, Bernareggi, Alberto, Schwartzberg, Lee
Publicado 2019

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

por Porter, I., Theodoulou, E., Holen, I., Harper-Wynne, C., Baron-Hay, S., Wilson, C., Brown, J.
Publicado 2021

Breast Radiotherapy after Oncoplastic Surgery—A Multidisciplinary Approach

por Metz, Gabrielle, Snook, Kylie, Sood, Samriti, Baron-Hay, Sally, Spillane, Andrew, Lamoury, Gillian, Carroll, Susan
Publicado 2022

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinant...

por Murphy, Caitlin, Muscat, Andrea, Ashley, David, Mukaro, Violet, West, Linda, Liao, Yang, Chisanga, David, Shi, Wei, Collins, Ian, Baron-Hay, Sally, Patil, Sujata, Lindeman, Geoffrey, Khasraw, Mustafa
Publicado 2019

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

por Friedlander, Michael, Mileshkin, Linda, Lombard, Janine, Frentzas, Sophia, Gao, Bo, Wilson, Michelle, Meniawy, Tarek, Baron-Hay, Sally, Briscoe, Karen, McCarthy, Nicole, Fountzilas, Christos, Cervantes, Andres, Ge, Ruimin, Wu, John, Spira, Alexander
Publicado 2023

A distinct molecular profile associated with mucinous epithelial ovarian cancer

por Heinzelmann-Schwarz, V A, Gardiner-Garden, M, Henshall, S M, Scurry, J P, Scolyer, R A, Smith, A N, Bali, A, Bergh, P Vanden, Baron-Hay, S, Scott, C, Fink, D, Hacker, N F, Sutherland, R L, O'Brien, P M
Publicado 2006

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

por Antill, Yoland, Kok, Peey-Sei, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Smith, Deborah, Spurdle, Amanda, Barnes, Elizabeth, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Andrews, John, Stockler, Martin R, Mileshkin, Linda
Publicado 2021

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

por Smith, Deborah, Robledo, Kristy P., Yip, Sonia, Cummins, Michelle M., Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda, Antill, Yoland
Publicado 2022

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

por Makker, Vicky, Colombo, Nicoletta, Herráez, Antonio Casado, Monk, Bradley J., Mackay, Helen, Santin, Alessandro D., Miller, David S., Moore, Richard G., Baron-Hay, Sally, Ray-Coquard, Isabelle, Ushijima, Kimio, Yonemori, Kan, Kim, Yong Man, Guerra Alia, Eva M., Sanli, Ulus A., Bird, Steven, Orlowski, Robert, McKenzie, Jodi, Okpara, Chinyere, Barresi, Gianmaria, Lorusso, Domenica
Publicado 2023